Multi-drug-resistant tuberculosis future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
Line 76: Line 76:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Tuberculosis]]
[[Category:Tuberculosis]]
[[Category:Infectious disease]]

Latest revision as of 18:06, 18 September 2017

Multi-drug-resistant tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multi-drug-resistant tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multi-drug-resistant tuberculosis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multi-drug-resistant tuberculosis future or investigational therapies

CDC on Multi-drug-resistant tuberculosis future or investigational therapies

Multi-drug-resistant tuberculosis future or investigational therapies in the news

Blogs on Multi-drug-resistant tuberculosis future or investigational therapies

Directions to Hospitals Treating Multi-drug-resistant tuberculosis

Risk calculators and risk factors for Multi-drug-resistant tuberculosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Since new drug resistant tuberculosis have been emerging, the role of future therapies is vital in curbing outbreaks. The new drugs should be more effective than the current regimen and a few drugs in clinical trials have been showing good results.

Future investigations

Principles of future investigations

Any future regimen should satisfy the following principles. [1]

  • It should not have more than a maximum duration of 6 months
  • The dosing schedule must be simple
  • The number of drugs in it should be ideally not more than 3-5 drug each from a different class
  • It should have minimum side effect profile so that we could have minimum monitoring
  • It should be effective against MDR, XDR and XXDR strains
  • It should be administered per orally
  • It should have minimum interaction with anti retroviral drugs.
  • It should have atleast one new class of drug

New drugs involved in clinical trial for treatment of tuberculosis

Drug Phase Class
Moxifloxacin Phase III Fluoroquinolone
Linezolid Phase II Oxazolidinone
AZD-5847 Phase II Oxazolidinone
Sutezolid Phase II Oxazolidinone
Clofazimine Phase II Riminophenazine
SQ-109 Phase II Ethylenediamine
PA-824 Phase IIb Nitroimidazole
Delamanid Phase III Nitroimidazole
Bedaquiline Phase III Diarylquinoline
Data provided by WHO[2]

References

  1. "Future therapy purposed by WHO".
  2. "Tuberculosis (TB) Future drugs".

Template:WH Template:WS